BCLI Brainstorm Cell Therapeutics Inc.

$-100%

17,193 Shares Traded
48,862 Average Volume (last 30 days)

as of February 23, 2018 EST IEX Real-Time Price

Short Pain Metrics

Approximate Amount of Money Shorts Have Made on the Day: $3.59 million
If Intiated on the First, Shorts Have Realized a Year to Date Return of:14.79%
If Intiated One Month Ago, Shorts Have Realized a Return of:13.85%
If Initiated Five Days ago, Shorts Have Realized a Return of:1.58%
Peer Potential Short Squeezes Near Real Time Screener
*Please note the actual returns of shorts could be different as they started from different points

Daily Indicators

Daily Short Pain Indicator [i] - Always Use Fundamentals on EverythingNeutral
200 Day Moving Average Indicator Bearish
50 Day Moving Average Indicator Bearish
52 Week High/Low Indicator Neutral

Short Stats

Short Percent to Float 7.68%
Short Interest1.14 million
Float14.79 million
Short Ratio14.4
Market Cap$58.6 million
Market Maker ActivityDaily Short Volume

News

02-07-2018
BrainStorm's NurOwn® Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles, California (PR Newswire)
02-06-2018
Your Daily Pharma Scoop: AMAG Gets Label Expansion For Feraheme, Bristol-Myers Squibb Reports Results, EyeGate Shares Tumble (SeekingAlpha)
02-06-2018
BrainStorm Cell Therapeutics to Present at the BIO CEO & Investor Conference (PR Newswire)
02-05-2018
BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors (PR Newswire)
01-16-2018
BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22 (PR Newswire)
01-10-2018
Brainstorm Cell Therapeutics (BCLI) Presents At 10th Annual Biotech Showcase 2018 - Slideshow (SeekingAlpha)
01-03-2018
BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn® (PR Newswire)
12-29-2017
Midday Gainers / Losers (SeekingAlpha)
12-29-2017
Brainstorm Issues 2017 Letter to Shareholders (PR Newswire)
12-29-2017
Your Daily Pharma Scoop: Heron Enters 2018 On Strong Note, Teva Launches Generic Reyataz, Sarepta Top Smid-Cap Pick (SeekingAlpha)


Smart Money Sentiment

Institutional Ownership (Top 15 Funds) 8.5%

Earnings Stats

PE Ratio -9.72
Dividend Yield 0%
Peer EarningsEarnings Calendar

Technicals

200 Day Moving Average $4.01
50 Day Moving Average $3.45
52 Week High $5.18
52 Week Low $2.88



Data provided for free by IEX. Questions? Read the FAQ